Sexual Dysfunction in Parkinson's Disease: What About Women?

60.7% of women with Parkinson's had sexual dysfunction vs 17.9% of controls — but the two measurement scales disagreed

Journal: Journal of the Neurological Sciences | Published: 2026-01-16 | Type: Cross-sectional observational study | PMID: 41581369 Authors: Panichelli et al. (Universidade Federal do Estado do Rio de Janeiro / State University of Rio de Janeiro) Funding/COI: Funding not listed; authors declare no competing interests

Summary

Women with Parkinson's disease (PD) experience sexual dysfunction at more than triple the rate of healthy age-matched controls, according to this small Brazilian cross-sectional study. Depression and dysautonomia correlated with dysfunction in PD patients, and dopamine agonist use was more common among the women without sexual dysfunction — a finding the authors flag as worth investigating further. The paper is more exploratory than definitive, which is appropriate given a sample of 28 patients.

Claims

• Sexual dysfunction was present in 60.7% of PD patients vs. 17.9% of controls using the Sexual Quotient–Female Version (SQF; p = 0.004)
• The Female Sexual Function Index (FSFI) showed no statistically significant difference between the groups — contradicting the SQF result
• PD patients with sexual dysfunction scored higher on the SCOPA-AUT (dysautonomia scale) and BDI-II (depression inventory)
• Dopamine agonist use was more frequent among PD patients without sexual dysfunction
• Women with PD reported equivalent subjective importance placed on sex compared to controls, despite higher dissatisfaction

Study Quality

This is a cross-sectional observational study — by design it can identify associations, not causation. The methodology is internally consistent for its aims: clinical data from PD patients with age-matched healthy controls, using validated questionnaires (SQF, FSFI, SCOPA-AUT, BDI-II). The matched-control design is appropriate.

The most damaging methodological issue is that the two primary sexual function scales gave conflicting results. The SQF reached significance (p = 0.004); the FSFI did not. The paper does not adequately explain this discrepancy. When your two instruments disagree, the headline finding is murkier than the abstract implies.

Red Flags

• Tiny sample: n=28 PD patients, n=28 controls. Underpowered for most subgroup analyses
• Scale conflict: SQF and FSFI gave different results — the paper leads with the significant one without fully accounting for the null result on FSFI
• Cross-sectional design: Cannot establish whether PD caused the dysfunction, or whether the dopamine agonist association is therapeutic or confounded by disease severity
• No multivariate adjustment: Dysautonomia, depression, and dopamine agonist use are all correlated with each other and with disease severity; their independent contributions can't be separated here
• Funding not reported: Unclear whether this study had institutional support or conflicts not captured by the COI declaration

Strengths

• Addresses a genuinely underexplored population — most PD sexual dysfunction research focuses on men
• Uses multiple validated instruments (SQF, FSFI, SCOPA-AUT, BDI-II)
• Age-matched control group included, which most studies in this space omit
• Honest framing of the dopamine agonist finding as hypothesis-generating rather than conclusive

Verdict

This paper documents a real gap: female sexual dysfunction in Parkinson's disease is understudied, and this group found rates (60.7%) substantially higher than controls. But with 28 patients, conflicting results across two validated scales, and no ability to adjust for confounders, the specific numbers shouldn't be taken as settled. The dopamine agonist signal is the most scientifically interesting piece and warrants a properly powered follow-up. Read this as a pilot study that justifies future work, not as evidence of anything definitive.